Silence Therapeutics plc — Form SCHEDULE 13D/A
Filed July 8, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 42/100
What the filing says
Richard Ian Griffiths and Cream Capital Limited sold 1,544,374 Silence Therapeutics ADSs over six trading days (June 29–July 6, 2026) at prices ranging from $10.47 to $10.76 per share, totaling approximately $16.2M. The filing is a joint Schedule 13D/A amendment disclosing these open-market sales by related reporting persons.
Why this rating
Sales represent ~7.9% of company market cap (~$16.2M/$206M). Insider liquidation signals possible loss of confidence, but magnitude is moderate and prices stable—not panic selling.
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.